Serine/Glycine-Free Diet in CRC Immunity

The reference study by Tong and colleagues, published in Cell Metabolism, examines how a serine/glycine-free diet, abbreviated as the −SG diet, reshapes colorectal cancer biology and antitumor immunity. Its central contribution is not simply the observation that nutrient restriction can slow tumor growth. Instead, the study identifies a dual response: dietary serine and glycine deprivation strengthens cytotoxic immune activity but also induces a tumor-cell adaptation involving PD-L1 lactylation. The full study is available through the reference paper.

Study Background and Research Question

Colorectal cancer remains difficult to treat immunologically, particularly in patients with mismatch repair-proficient or microsatellite-stable disease. Although PD-1 inhibitors can produce substantial responses in selected mismatch repair-deficient or microsatellite instability-high tumors, most pMMR/MSS colorectal cancers derive limited benefit. The reference study notes that more than 85% of patients fall into the group with limited response to current checkpoint immunotherapy, emphasizing the need to modify the tumor immune environment rather than rely on checkpoint blockade alone.

Serine and glycine are important metabolic substrates for cancer-cell proliferation, redox balance, nucleotide production, and biosynthetic adaptation. Tumors can obtain these amino acids from the extracellular environment or synthesize them through intracellular pathways. At the same time, accelerated glycolysis generates lactate, which is increasingly recognized as a signaling metabolite rather than merely a by-product. Tong et al. therefore asked whether removing dietary serine and glycine would influence both tumor metabolism and immune surveillance, and whether the resulting response might alter the effectiveness of PD-1 or PD-L1-targeted therapy.

Key Innovation from the Reference Study

The innovative aspect of the work is the identification of an immunological benefit and an immune-evasion liability within the same dietary intervention. The −SG diet inhibited colorectal tumor growth and promoted the accumulation of cytotoxic T cells. This finding supports the concept that systemic nutrient availability can influence immune-cell recruitment or activity in the tumor microenvironment, rather than acting only through direct metabolic stress on malignant cells.

However, the diet also increased a post-translational modification of PD-L1 known as lactylation in tumor cells. According to the study, PD-L1 lactylation delayed lysosome-mediated degradation of PD-L1. Stabilized PD-L1 can maintain inhibitory signaling toward PD-1-expressing T cells, creating a route for tumor immune evasion even as the diet increases cytotoxic T-cell presence. This finding gives lactylated PD-L1 potential value as a mechanistic target and explains why enhanced immune infiltration does not automatically translate into complete tumor control.

The paper consequently reframes dietary intervention as a context-dependent modifier of immunotherapy. The −SG diet may make tumors more immunologically visible or more heavily infiltrated, while checkpoint blockade may be needed to prevent the tumor from exploiting the resulting PD-L1 stabilization.

Methods and Experimental Design Insights

The study used a translational design that connected tumor-growth experiments, immune analysis, molecular mechanism studies, and an early clinical investigation. In the preclinical component, the investigators evaluated how the −SG diet affected colorectal tumor progression and the composition or activity of antitumor immune cells. The reported increase in cytotoxic T-cell accumulation was important because it connected dietary manipulation with a specific effector arm of cancer immunity rather than with a nonspecific change in tumor size.

The mechanistic experiments focused on PD-L1 regulation in tumor cells. The investigators examined PD-L1 lactylation and its relationship to protein stability and lysosomal degradation. This approach moved beyond measuring total PD-L1 abundance: it addressed how a chemical modification can change the fate of the checkpoint protein. Functional experiments involving PD-1/PD-L1 pathway blockade then tested whether interrupting checkpoint signaling could restore the activity of CD8+ T cells recruited under the −SG diet. The logic of this design is strengthened by the use of complementary observations: dietary treatment, immune-cell behavior, molecular modification, protein turnover, and response to checkpoint blockade were considered together.

The clinical translation consisted of a single-arm, phase I study registered as ChiCTR2300067929. The primary clinical objective was feasibility and safety in the context of systemic immune regulation, while tolerability and possible antitumor activity were secondary considerations. Because the clinical study was single-arm, it was designed to establish whether the dietary strategy could be implemented and monitored, not to provide definitive comparative evidence of efficacy. The clinical component therefore complements, but does not replace, the mechanistic evidence from the experimental models.

Protocol Parameters

• Diet intervention: Reproduce the serine/glycine composition, treatment schedule, nutritional monitoring, and compliance procedures reported in the reference study; these parameters should not be inferred from the condensed findings alone.
• Immune endpoints: Pair tumor-growth measurements with quantitative and functional assessment of CD8+ or other cytotoxic T-cell responses so that immune recruitment is not confused with effective tumor killing.
• Checkpoint mechanism: When investigating PD-L1 regulation, distinguish total protein abundance from lactylation status and degradation behavior. These are study-derived mechanistic endpoints, not interchangeable measurements.
• DNA synthesis readout: For cultured-cell follow-up experiments, an EdU pulse can provide a complementary cell cycle S-phase DNA synthesis measurement. Pulse duration and concentration should be optimized for the cell model and treated as workflow recommendations rather than parameters reported by the reference study.
• Fluorescence workflow: Copper-catalyzed azide-alkyne cycloaddition (CuAAC) can support click chemistry DNA synthesis detection after EdU incorporation. Include viability controls, appropriate fluorescence controls, and compensation or unmixing controls when combining the readout with immune or cell-cycle markers.

Core Findings and Why They Matter

First, the −SG diet suppressed colorectal tumor growth in the experimental setting. This result is consistent with the dependence of many tumors on exogenous nutrients and suggests that dietary composition can alter the metabolic conditions under which malignant cells compete with immune cells. The result should not be interpreted as evidence that nutrient restriction alone is sufficient therapy, because tumor cells may compensate through biosynthesis, tissue-derived nutrients, or other metabolic routes.

Second, the diet enhanced antitumor immunity by promoting the accumulation of cytotoxic T cells. This is especially relevant to pMMR/MSS colorectal cancer, where poor immune-cell infiltration is one factor associated with resistance to checkpoint therapy. The study provides a rationale for combining metabolic or nutritional remodeling with immunotherapy to improve the cellular context in which PD-1/PD-L1 blockade operates.

Third, the work identifies PD-L1 lactylation as a counter-regulatory mechanism. By delaying lysosomal degradation, this modification helps maintain PD-L1 on tumor cells and can weaken T-cell-mediated control. The implication is therapeutically important: increasing T-cell infiltration without addressing checkpoint stabilization may produce an incomplete response. In the study, blocking the PD-1/PD-L1 pathway rejuvenated the function of CD8+ T cells recruited by the diet, supporting a combination approach.

Finally, the phase I clinical findings indicate that the −SG diet was feasible and safe for regulating systemic immunity in the studied setting. These observations are encouraging but preliminary. Feasibility demonstrates that the intervention can be delivered and monitored; it does not establish a survival advantage or prove that the preclinical mechanism operates identically in every patient.

Comparison with Existing Internal Articles

The internal overview Serine/Glycine-Free Diet: Dual Roles in Colorectal Cancer Immunity provides a concise synthesis of the same central paradox: tumor suppression and immune activation occur alongside PD-L1-mediated escape. The present analysis places greater emphasis on experimental logic, the distinction between immune recruitment and immune effectiveness, and the limitations of translating a single-arm clinical study into treatment recommendations.

A different methodological perspective appears in Practical Use of EdU Flow Cytometry Assay Kits (Cy5) for Cell Proliferation. That article addresses assay implementation rather than the dietary mechanism. Its relevance here is complementary: DNA synthesis measurements can help determine whether dietary or immunotherapeutic conditions alter proliferation in cultured tumor cells, but an EdU signal cannot by itself establish T-cell function, PD-L1 lactylation, or tumor regression.

Limitations and Transferability

The clinical evidence has the clearest limitation: a single-arm phase I design lacks a randomized comparator. It can characterize implementation, tolerability, and exploratory biological or antitumor signals, but it cannot reliably separate treatment effects from patient selection, background therapy, natural disease variation, or nutritional changes that accompany clinical care. Larger controlled studies will be required before the diet can be considered an established adjunct to checkpoint therapy.

Preclinical transferability is also uncertain. Nutrient availability differs among tumor sites, host tissues, microbiota, and patients with different nutritional or metabolic states. A diet that produces a beneficial immune context in colorectal cancer models may not generate the same amino-acid or lactate environment in another tumor type. The extent to which PD-L1 lactylation is a dominant resistance mechanism may likewise vary with tumor genotype, glycolytic activity, immune composition, and treatment history.

Mechanistic interpretation requires careful endpoint matching. Increased CD8+ T-cell abundance does not necessarily mean increased cytotoxicity, and reduced tumor growth does not identify whether the dominant effect was direct metabolic stress, immune activation, or both. Similarly, measuring PD-L1 expression without measuring its modification and turnover would miss the specific mechanism proposed by the study. These distinctions should guide validation experiments and prevent overextension of the findings.

Why this cross-domain matters, maturity, and limitations

The bridge from immunometabolism to cell-proliferation analysis is useful because the −SG diet can affect both tumor-cell division and immune-cell behavior. A flow cytometry cell proliferation assay based on EdU incorporation can quantify DNA synthesis in defined cell populations, helping researchers compare treated and untreated tumor cells or characterize proliferation within an ex vivo model. It is an analytical complement to the reference study, not a replacement for immune phenotyping, lactylation assays, protein-degradation studies, or in vivo tumor measurements.

This application is therefore at a supportive experimental stage. It is most informative when combined with cell identity markers, viability measurements, cell-cycle analysis, and independent functional endpoints. EdU-based data should not be presented as direct evidence of clinical benefit or as proof that PD-L1 lactylation caused a particular proliferation phenotype. The strongest interpretation comes from integrating DNA synthesis with the molecular and immune endpoints already established in the reference paper.

Research Support Resources

For researchers extending these experiments to cultured tumor or immune-cell systems, EdU Flow Cytometry Assay Kits (Cy5) (SKU K1078) can support a 5-ethynyl-2'-deoxyuridine cell proliferation assay. The workflow uses EdU incorporation followed by copper-catalyzed azide-alkyne cycloaddition with a Cy5 azide signal, avoiding the harsh DNA-denaturation step associated with many BrdU protocols and supporting multiplexing with cell-cycle dyes or antibodies. It should be used as a complementary research readout for DNA synthesis, not as a clinical diagnostic or a standalone measure of antitumor immunity.